Tirabrutinib hydrochloride is a Small Molecule owned by Ono Pharmaceutical, and is involved in 23 clinical trials, of which 15 were completed, and 8 are ongoing.
Tirabrutinib covalently binds to Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase and member of the Tec family of kinases, which plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. The binding of tirabrutinib to BTK within B cells, thereby prevents the B cell receptor signaling and impeding B cell development. This results in inhibition of proliferation of B cell malignancies.
The revenue for Tirabrutinib hydrochloride is expected to reach a total of $110m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tirabrutinib hydrochloride NPV Report.
Tirabrutinib hydrochloride Overview
Tirabrutinib hydrochloride (Velexbru) is a antineoplastic agent. It is formulated as film coated tablet for oral route of administration. Velexbru is indicated for the treatment of recurrent or refractory primary central nervous system, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma
Tirabrutinib hydrochloride (ONO-4059, ONO-WG-307, GS-4059) is under development for the treatment of systemic sclerosis, relapsed or refractory primary central nervous system lymphoma (PCNSL), relapsed/refractory non-Hodgkin lymphomas such as follicular lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma, marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), relapsed or refractory chronic lymphocytic leukemia, primary central nervous system lymphoma, and chronic spontaneous urticaria (CSU). The new chemical entity is formulated as tablet or capsule which is administered orally and targets bruton’s tyrosine kinase (Btk).
It was also under development for the treatment of rheumatoid arthritis, Sjogren syndrome, pemphigus, B-cell chronic lymphocytic leukemia and autoimmune disorders.
Gilead Sciences Overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.
Quick View – Tirabrutinib hydrochloride
|Highest Development Stage|